At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-Controlled, Randomized Trial of Ensitrelvir (S-217622) for Viral Persistence and Inflammation in People Experiencing Long COVID (PREVAIL-LC)
In Brief
A Phase 2 clinical trial evaluating Ensitrelvir and Placebo for Long COVID and 2 related conditions. Active but no longer recruiting, targeting 40 participants across 1 site.
Detailed Summary
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population.
Study Details
Timeline
Interventions
Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
Matching placebo for Ensitrelvir